Dr. Finkelstein is a Professor of Pediatrics, Pharmacology and Toxicology, the University of Toronto and a Senior Clinician-Scientist at The Hospital for Sick Children.

He holds the Canada Research Chair in Pediatric Drug Safety and Efficacy (Tier I). Dr. Finkelstein is quadruple-trained in paediatrics, medical toxicology, clinical pharmacology, and pediatric emergency medicine. Between 2008 and 2015 he served as a Visiting Professor at Boston Children’s Hopital, Harvard Medical School.

The overarching goal of Dr. Finkelstein’s research program focuses on optimizing therapeutics and outcomes of sick and injured children in acute care settings, with a major focus on prevention of accidental and intentional drug overdose and subsequent suicide and their interface with mental health, employing epidemiological, randomized clinical trials and precision medicine tools.

Since 2016, Yaron has been serving as a “Thought Leader” for NIH’s Pediatric Trials Network, an alliance of >200 hospitals, working for drug label modifications for children at FDA. Dr. Finkelstein also established and leads the American College of Medical Toxicology Pediatric Marijuana & Opioids (PEDMOP) Toxicology Investigators Consortium (ToxIC) sub-registries, and is a member of the Canadian Paediatric Society Drugs and Hazardous Substances Committee. Yaron is the author of >200 peer-reviewed articles in leading medical journals (e.g., NATURE Comm, New England Journal of Medicine, JAMA, Lancet Psych), and has written numerous book chapters. His research has been cited >7300 times by other research groups, and he is frequently a “go-to” person for the media.